Table 2.

Hearing and Imaging Response Data During 12 Months of Bevacizumab Treatment

Response	Overall Response		Confirmed Response*
	No.	%	No.	%
Hearing
Target ear	8 of 14	57	5 of 14	36
Contralateral ear	4 of 5	80	4 of 5	80
All ears	12 of 19	63	9 of 19	47
Imaging
Target VS
PR (≥ 20% decrease)	6 of 14	43	2 of 14	14
MR (5%–19% decrease)	4 of 14	29	7 of 14	50
SD	4 of 14	29	5 of 14	36
PD (≥ 20% increase)	0 of 14	0	0 of 14	0
Contralateral VS
PR (≥ 20% decrease)	6 of 14	43	3 of 14	21
MR (5%–19% decrease)	6 of 14	43	6 of 14	43
SD	2 of 14	14	5 of 14	36
PD (≥ 20% increase)	0 of 14	0	0 of 14	14

Abbreviations: MR, minor response; PD, progressive disease; PR, partial response; SD, stable disease; VS, vestibular schwannoma.

^*Confirmed response was defined as maintained across two evaluations at least 3 months apart.